- $60.35m
- $27.07m
- 45
- 31
- 91
- 56
Annual balance sheet for ARCA biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 8.36 | 49.1 | 53.4 | 42.4 | 37.4 |
Total Other Current Assets | |||||
Total Current Assets | 8.48 | 50 | 54.4 | 42.7 | 37.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.032 | 0.449 | 0.485 | 0.368 | 0.257 |
Other Long Term Assets | |||||
Total Assets | 8.54 | 50.4 | 54.9 | 43.1 | 37.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.926 | 3.5 | 3.5 | 1.13 | 0.637 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.926 | 3.91 | 3.88 | 1.41 | 0.841 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 7.61 | 46.5 | 51 | 41.7 | 37 |
Total Liabilities & Shareholders' Equity | 8.54 | 50.4 | 54.9 | 43.1 | 37.9 |
Total Common Shares Outstanding |